ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Psoriatic arthritis"

  • Abstract Number: 0586 • ACR Convergence 2025

    Immune Checkpoint agonists: A New horizon for treatment of psoriatic arthritis

    Siba Raychaudhuri1, Christine Abria2 and Smriti K Raychaudhuri3, 1UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, 2Sacramento VA Medical Center, Mather, CA, 3Sacramento VA Medical Center, Davis, CA

    Background/Purpose: Check point inhibitor PD-1 (programmed death protein 1) is upregulated during T lymphocyte activation and is important for limiting the duration of activation. Thus,…
  • Abstract Number: 2613 • ACR Convergence 2025

    Ga-FAPI-04 PET/CT reveals increased fibroblast activation in synovial and enthesial tissues of psoriasis patients with arthralgia and predicts the development of psoriatic arthritis

    Giulia Corte1, Koray Tascilar2, armin Atzinger3, Alp Temiz2, Melek Yalcin Mutlu4, Rita Noversa de Sousa5, Maria Gabriella Raimondo6, Andreas Ramming7, Sara Bayat2, Michael Sticherling8, Torsten Kuwert9, Christian Schmidkonz9, Georg Schett10 and Filippo Fagni11, 1- Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 2Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, 3Department of Nuclear Medicine, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 4Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, erlangen, 5Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, 6Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 7Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, 8Department of Dermatology, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 9Department of Nuclear Medicine, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, 10Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 11Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany

    Background/Purpose: 68Ga-FAPI-04 PET/CT reveals fibroblast activation in vivo and is increasingly used to assess rheumatic diseases, including inflammatory arthritides. (1,2) We previously demonstrated that the…
  • Abstract Number: 2362 • ACR Convergence 2025

    Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 1 Trial

    Mauro Keiserman1, Kim Papp2, Douglas White3, Angela Crowley4, Joseph F Merola5, Hayley Barnard6, Ana Biljan7, Thomas Iyile8, Lingfeng luo6, Douglas Ashley6, Arathi Setty8, Hayato Yamazaki6 and Frank Behrens9, 1Rheumatology Section, Pontifical Catholic University, School of Medicine, Porto Alegre, Brazil, 2Probity Medical Research and Alliance Clinical Trials, Waterloo, and Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, 3Rheumatology Department, Waikato Hospital, Hamilton, New Zealand, 4Willow Rheumatology and Wellness, Willowbrook, IL, 5Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, 6AbbVie Inc., North Chicago, IL, 7AbbVie Inc., Buffalo Grove, IL, 8AbbVie Inc, North Chicago, IL, 9Goethe-University & Fraunhofer ITMP, Frankfurt, Germany

    Background/Purpose: Risankizumab (RZB), an anti-interleukin 23p19 monoclonal antibody, is approved for the treatment of adults with active PsA. We report the efficacy and safety of…
  • Abstract Number: 2321 • ACR Convergence 2025

    Uncovering Clinical Phenotypes of Sexual Dysfunction in Spondyloarthritis: A Multidimensional Analysis

    Martín Valdez-López1, Ana Barrera-Vargas1, Javier Merayo-Chalico2, Irazú Contreras-Yañez3, Carlos Abdiel Abitia Borboa4, Iris Paola García-Herrera1, Raúl Pérez-Gamboa1 and Guillermo Arturo Guaracha-Basáñez1, 1Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Tlalpan, Distrito Federal, Mexico, 2Reumátika, Centro de Vanguardia en Reumatología, Ciudad de México, Federal District, Mexico, 3Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Tlalpan, Mexico, 4Universidad Autónoma de Sinaloa Facultad de Medicina Culiacán, Culiacan, Sinaloa, Mexico

    Background/Purpose: Spondyloarthritis (SpA) impacts patient’s life, including functionality, QoL, emotional state, and sexual function. The current study was conducted to determine the frequency of sexual…
  • Abstract Number: 1911 • ACR Convergence 2025

    Characterizing Psoriasis Patients at Risk for Transition to Psoriatic Arthritis: Early Insights from the STOP PsA At-Risk Cohort

    Victoria Konzett1, Eva Manger2, Simon Reider2, Johannes Griss3, Constanze Jonak3, Kastriot Kastrati4, Peter Mandl4, Gudrun Ratzinger5, Christina Duftner2, Thomas Karonitsch4 and Daniel Aletaha6, 1Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria, 3Department of Dermatology, Medical University of Vienna, Austria, Vienna, Austria, 4Department of Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, 5Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Austria, Innsbruck, Austria, 6Medical University Vienna, Wien, Austria

    Background/Purpose: Psoriatic arthritis (PsA) develops predominantly in patients with psoriasis (Pso). Although key drivers and predictors of disease progression have been identified in recent years,…
  • Abstract Number: 1459 • ACR Convergence 2025

    Fungal Infections, Including Candida, in Patients With Active Psoriatic Arthritis (PsA) Treated With Secukinumab: A Pooled Analysis of 9 Phase 3 Trials

    Shikha Singla1, Linda Grinnell-Merrick2, Weibin Bao3, Artem Zharkov4 and Abhijeet Danve5, 1Medical College of Wisconsin, Milwaukee, WI, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, 3Novartis Pharmaceuticals Corporation, Hanover, NJ, 4Novartis Pharma AG, Basel, Switzerland, 5Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT

    Background/Purpose: PsA is a chronic inflammatory disease characterized by joint pain, swelling and stiffness, and is often accompanied by cutaneous changes linked to psoriasis. Patients…
  • Abstract Number: 1426 • ACR Convergence 2025

    Understanding the Drivers of BASDAI and Back Pain Scores in Psoriatic Arthritis

    Pankti Mehta1, Fadi Kharouf2, Virginia Carrizo Abarza3, Shangyi Gao4, Dafna D. Gladman5, Vinod Chandran6 and Denis Poddubnyy7, 1University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, 2University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 3University of Toronto, Toronto, 4Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, 5Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, 6University of Toronto, Toronto, ON, Canada, 7Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany

    Background/Purpose: The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is the most commonly used tool to assess axial disease in psoriatic arthritis (PsA). However, five…
  • Abstract Number: 1095 • ACR Convergence 2025

    Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series

    dellal azeddine1, Jean-Guillaume Letarouilly2, Jacques Morel3, René-Marc Flipo4, Valerie Devauchelle5, richette pascal6, Philippe Dieude7, Hubert Marotte8, FELTEN Renaud9, LATOURTE Augustin10, CHEVET Baptiste11, HILLIQUIN Pascal12, SORDET Christelle9, DERNIS mmanuelle13, WENDLING Daniel14, Arsène Mekinian15, Nathalie BALLANDRAUD16, Christophe Richez17, TOURNADRE Anne18, salmon Jean -Hugues19, SAILLOT Carine20, kedra joanna21, nahon stephane22, LE GOFF Benoit23, Bruno Fautrel24, Francis BERENBAUM25, David SAADOUN26, PHAM Thao16 and SELLAM JEREMIE27, 1GHI LE RAINCY MONTFERMEIL, Montfermeil, France, 2Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, LILLE, Nord-Pas-de-Calais, France, 3CHU and University of Montpellier, Montpellier, France, 4Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, 5UBO, Brest, France, 6Rheumatology Department, Lariboisiere Hospital, Paris, Ile-de-France, France, 7Service de Rhumatologie, Hôpital Bichat APHP, Paris, Paris, Ile-de-France, France, 8INSERM 1059/University of Saint-Etienne, Saint-Etienne, France, 9Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, 10Rheumatology Department, Lariboisiere Hospital, Paris, France, 11CHU BREST, brest, Bretagne, France, 12CH SUD FRANCILIEN, PARIS, France, 13chu caen, CAEN, Haute-Normandie, France, 14CHU de Besançon, Besançon, Franche-Comte, France, 15Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i3), Saint-Antoine University Hospital, 75012 Paris, France, Paris, France, 16CHU MARSEILLE, marseille, Provence-Alpes-Cote d'Azur, France, 17Bordeaux University Hospital, Bordeaux, France, 18CHU CLERMONT, CLERMONT, Lorraine, France, 19CHU REIMS, REIMS, Champagne-Ardenne, France, 20CHU ORLEANS, ORLEANS, Pays de la Loire, France, 21Pitié-Salpêtrière Hospital, Rheumatology Department, APHP, Sorbonne University,, Paris, France, 22GHI LE RAINCY MONTFERMEIL, Montfermeil, Ile-de-France, France, 23CHU Nantes, Nantes, France, 24Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS 1136-5, PARIS, France, Paris, France, 25Sorbonne University/Inserm/AP-HP/4Moving Biotech, Paris, France, 26CHU LA PITIE SALPETRIERE, PARIS, Ile-de-France, France, 27Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France, /Rheumatology Department, AP-HP Saint-Antoine Hospital, 184, rue du Faubourg Saint-Antoine, 75012, Paris, France., Paris, France

    Background/Purpose: The use of TNFα antagonist is not recommended if the patient have a suspicion or demyelinating diseases (DD) confirmed [1]. There are a few…
  • Abstract Number: 0567 • ACR Convergence 2025

    Sonelokimab in Biologic-Experienced Patients With Active Psoriatic Arthritis: Results From a Phase 2 Trial (ARGO) and Study Design of a Phase 3 Trial (IZAR-2) in Patients With Inadequate Response or Intolerance to Biologic TNFi, Including a Risankizumab Reference Arm

    Atul Deodhar1, Laure Gossec2, Philip J. Mease3, Xenofon Baraliakos4, Lihi Eder5, Alan Kivitz6, Helena Marzo-Ortega7, Frank Behrens8, Ana-Maria Orbai9, Georg Schett10, Arthur Kavanaugh11, Dennis McGonagle12, Christopher Ritchlin13, Nuala Brennan14, Ben Porter-Brown14, Eva Cullen14, Matthew R. Thomas14, Marius Albulescu14, Alex Godwood14, Kristian Reich15 and Laura Coates16, 1Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 2Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, 3Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, 4Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 5University of Toronto, Toronto, ON, Canada, 6Altoona Center for Clinical Research, Duncansville, PA, 7NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, 8Rheumatology, Immunology - Inflammation Medicine, University Hospital Goethe-University & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany, 9Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 10Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 11University of California, San Diego, School of Medicine, San Diego, CA, 12Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, 13University of Rochester Medical Center, Canandaigua, NY, 14MoonLake Immunotherapeutics AG, Zug, Switzerland, 15MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, 16Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom

    Background/Purpose: Sonelokimab (SLK), a novel Nanobody that binds to both IL-17A and IL-17F with similarly high affinity, is designed to target difficult-to-reach sites of inflammation.…
  • Abstract Number: 0549 • ACR Convergence 2025

    High Prevalence of Obstructive Sleep Apnea in Psoriatic Arthritis: A Polysomnography-Based Cross-Sectional Study

    Suzan Attar1, Siraj Walli2, Yasser Bawazir3, Mohammad Mustafa4, Ayah Boudal5, Faris alhejailli2, Ahmad Bamagoos2 and Omar Kanbr2, 1King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia, 2KAU, Jeddah, Saudi Arabia, 3King Abdulaziz University, Jeddah, Saudi Arabia, 4Jeddah University, Jeddah, Saudi Arabia, 5King Abdullah Medical Complex, Jeddah, Saudi Arabia

    Background/Purpose: Background: Obstructive sleep apnea (OSA) is increasingly recognized in patients with psoriatic arthritis (PsA), yet few studies have used polysomnography (PSG)—the gold-standard diagnostic method.…
  • Abstract Number: 0405 • ACR Convergence 2025

    Juvenile Psoriatic Arthritis and Enthesitis-Related Arthritis: 4-Year Results From the JUNIPERA Extension Study

    Hermine Brunner1, Ivan Foeldvari2, Gerd Horneff3, Antonio Mera Varela4, Angelo Ravelli5, Sharonjeet Kaur6, Swapnil Suhas Dahale7, Ruvie Martin8, Daniel Lovell1, Alberto Martini9 and Nicolino Ruperto10, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Hamburger Zentrum fuer Kinder und Jugendrheumatologie, Rheumatology, Hamburg, Germany, 3Asklepios Klinik, Hamburg, Germany, 4Rheumatology Division. Hospital Clínico Universitario de Santiago and Instituto de Investigaciones Sanitarias (IDIS), School of Medicine, Santiago de Compostela, Spain, 5IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, 6Novartis Pharma AG, Basel, Switzerland, 7IQVIA, Mumbai, India, 8Novartis Pharmaceuticals Corporation, East Hanover, NJ, 9Università di Genova, Genova, Italy, 10Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy

    Background/Purpose: Secukinumab demonstrated efficacy and safety in patients with juvenile idiopathic arthritis (JIA), including enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA), for up to…
  • Abstract Number: 0583 • ACR Convergence 2025

    Baseline Peripheral Phenotypes Are Associated with Differential Response to TNF Inhibitors in Psoriatic Arthritis. A Cluster Analysis Approach

    Raquel Granados1, Jesús Eduardo Martín Salazar2, María Ángeles Puche-Larrubia3, Pedro Ortiz Buitrago4, María Dolores López-Montilla5, Jerusalén Calvo6, Rafaela Ortega-Castro7, Montserrat Romero-Gómez8, Alejandro Escudero-Contreras9, Nuria Barbarroja10 and Clementina López Medina11, 1Hospital Universitario Reina Sofia, Cordoba, Andalucia, Spain, 2Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba/ Reina Sofia University Hospital, Rheumatology service/Department of Medical and Surgical Sciences, Cordoba, Spain, Cordoba, Andalucia, Spain, 3Reina Sofia University Hospital, Granada, Spain, 4Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, 5Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, 6IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 7Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 8Reina Sofia University Hospital, Cordoba, Andalucia, Spain, 9Reina Sofia University Hospital/Maimonides Institute of Biomedical Research of Córdoba(IMIBIC)/University of Cordoba, Cordoba, Andalucia, Spain, 10Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 11Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain

    Background/Purpose: Previous studies have identified subgroups of patients with psoriatic arthritis (PsA) based on the severity of the disease [1,2]. However, no analysis to date…
  • Abstract Number: 2608 • ACR Convergence 2025

    Metabolic dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factors, and Cardiac Manifestations in Psoriasis

    Maria Dons1, Charlotte Näslund-Koch2, Morten Sengeløv3, Sofie Bøgh-Sørensen3, Kristoffer Skaarup3, Marianne Bengtson Løvendorf4, Filip Davidovski3, Anne Marie Reimer Jensen3, Brittany Weber5, Lise Lotte Gluud6, Claus Zachariae2, Lone Skov2 and Tor Biering-Sørensen3, 1Copenhagen University Hospital Gentofte, Copenhagen, Hovedstaden, Denmark, 2Dep. of Dermatology and Allergy, Copenhagen University Hospital – Herlev & Gentofte, Copenhagen, Hovedstaden, Denmark, 3Center for Translational Cardiology and Pragmatic Randomized Trials, Dep. of Cardiology, Copenhagen University Hospital - Gentofte, Copenhagen, Hovedstaden, Denmark, 4Department of Dermatology and Allergy, Copenhagen University Hospital – Herlev & Gentofte, Copenhagen, Hovedstaden, Denmark, 5Brigham and Women's Hospital, DEDHAM, MA, 6Gastro Unit, Copenhagen University Hospital – Hvidovre, Copenhagen, Hovedstaden, Denmark

    Background/Purpose: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a cardiometabolic risk factor. Individuals with psoriasis have a high prevalence of MASLD, yet…
  • Abstract Number: 2357 • ACR Convergence 2025

    Impact of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Active Psoriatic Arthritis: Key Subgroup Analyses in the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial

    Lihi Eder1, Iain McInnes2, Christopher Ritchlin3, Alexis Ogdie4, Arthur Kavanaugh5, Laura Coates6, Georg Schett7, Alan Kivitz8, Nuala Brennan9, Alex Godwood9, Matthew R. Thomas9, Eva Cullen9, Kristian Reich10, Joseph F Merola11 and Philip J. Mease12, 1University of Toronto, Toronto, ON, Canada, 2University of Glasgow, Glasgow, United Kingdom, 3University of Rochester Medical Center, Canandaigua, NY, 4University of Pennsylvania, Philadelphia, PA, 5University of California, San Diego, School of Medicine, San Diego, CA, 6Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, 7Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 8Altoona Center for Clinical Research, Duncansville, PA, 9MoonLake Immunotherapeutics AG, Zug, Switzerland, 10MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, 11Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, 12Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA

    Background/Purpose: PsA is a chronic inflammatory disease affecting heterogeneous tissues, with unmet need for therapies with robust efficacy across disease domains. Sonelokimab (SLK) is a…
  • Abstract Number: 2320 • ACR Convergence 2025

    Sleep Disturbance in Psoriatic Arthritis: Prevalence by Minimal Disease Activity Status and Associated Clinical Factors

    Lourdes Perez Chada1, Vivi Feather2, Grace Carter2, Helen Early3, Emily Tsai2, Jing Cui4, Avery LaChance5, Rochelle Castillo6, Neda shahriari2, Alexis Ogdie7, Monika Haack2, Elizabeth Klerman2, Michael Weinblatt8, Nancy Shadick9, Joseph Merola10 and Chinmayi Naik3, 1Harvard Medical School, Wayland, MA, 2Mass General Brigham, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Brigham Women's Hospital, Boston, MA, 5Brigham and Women's Hospital, Jamaica Plain, MA, 6Brigham and Women's Hospital, Brookline, MA, 7Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, 8Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 9Brigham & Women's Hospital, Boston, MA, 10UT Southwestern Medical Center, Dallas, TX

    Background/Purpose: Sleep disturbance is a common and burdensome symptom in psoriatic arthritis (PsA), but its clinical determinants remain poorly understood. Using data from the Cohort…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 93
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology